A research team led at Texas A&M University reports a nasal spray therapy that reverses signs of brain aging in preclinical models. Age-related brain inflammation, sometimes called neuroinflammaging, can harm memory and increase risk of disorders such as Alzheimer’s disease.
The spray delivers millions of extracellular vesicles (EVs) carrying microRNAs directly to the brain through intranasal delivery. This route lets the EVs bypass the brain’s protective barrier and enter brain tissue. In two doses the treatment reduced inflammation, reactivated neuronal mitochondria and lowered oxidative stress, which improved the brain’s ability to process and store information.
Tests showed treated models did better at recognising familiar objects and detecting new objects or changes, and the results were similar in both sexes. The team published the findings in a scientific journal, filed a US patent, and received support from the National Institute on Aging. Further work is needed to assess safety, dosing and effects in humans.
Difficult words
- preclinical — before human testing, done in lab or animals
- neuroinflammaging — long-term inflammation in the brain with aging
- extracellular vesicle — small particles released by cells that carry moleculesextracellular vesicles
- microRNA — tiny pieces of genetic material that control genesmicroRNAs
- intranasal delivery — giving medicine through the nose to the brain
- mitochondrion — cell part that makes energy for nerve cellsmitochondria
- oxidative stress — cell damage caused by reactive oxygen molecules
- recognise — see or remember something seen beforerecognising
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- What concerns would you have about using this nasal spray in people? Explain briefly.
- Why is it important to study safety, dosing and effects in humans before using a new treatment?
- If this treatment worked in people, how could it change life for older adults?
Related articles
Affordable twice-yearly HIV injection lenacapavir to reach 120 countries
Lenacapavir, a twice-yearly HIV prevention injection, will be licensed for 120 low- and middle-income countries at US$40 a year. Rollout is expected from 2027 with funding support, but some countries and price transparency remain concerns.
Calcium and vitamin D for older adults' bone health
Bone expert Bess Dawson-Hughes says older adults should check their calcium and vitamin D to protect bones and reduce falls and fractures. Practical advice includes eating dairy, sensible supplements, and getting sunlight when possible.
More brain activity in OCD during a sequence task
A Brown University study found that people with obsessive-compulsive disorder (OCD) show extra brain activity when doing a demanding sequence task in an MRI. The findings point to new brain targets that might improve transcranial magnetic stimulation (TMS) treatment.
